Andrew Kolodziej

Andrew Kolodziej possesses extensive expertise in regulatory toxicology and drug development, currently serving as Executive Director at Corbus Pharmaceuticals since July 2020, where leadership includes overseeing mAb-based oncology programs and toxicology studies for cannabinoid receptor modulators. Prior roles include Senior Director of Toxicology at Keros Therapeutics and Vice President of Nonclinical Safety and CMC at Flatley Discovery Lab, where Andrew led toxicological support for clinical development in cystic fibrosis therapies. Notable experience also includes positions at EPIX Pharmaceuticals, Eutropics Pharmaceuticals, and Collagen Medical, where Andrew significantly contributed to drug discovery, development, and collaborations in various therapeutic areas. Educational background includes a Ph.D. in Chemistry from the Massachusetts Institute of Technology and a B.S. in Chemistry from the University of Chicago.